BALTIMORE, Nov. 15, 2016 /PRNewswire/ -- Ingenuity Health, a leading provider of medication monitoring solutions to behavioral
"Using urine drug monitoring is still a very new concept in behavioral health, and this study will give us a solid understanding of how clinicians are utilizing it now, and how it's helping those same clinicians in treating their patients," said Ameritox Chief Medical Officer Thomas Smith, MD.
The UCLA Center for Health Services and Society was selected for their expertise in enhancing the health of communities; access to and quality of care; and qualitative research. All Center publications undergo a rigorous peer review process to verify the accuracy of findings and to gauge their relevance and utility to intended audiences.
The research findings will be announced by both Ameritox and the UCLA Center for Health Policy Research. Please visit http://hss.semel.ucla.edu for more information about this research institution.
About Ingenuity Health As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.
Visit the Ingenuity Health website at: www.ingenuityhealth.com Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth
About Ameritox Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.
Visit the Ameritox website at: www.ameritox.com Follow Ameritox on Twitter: www.twitter.com/ameritox
Contact: Genevieve Rozansky 30 Point Strategies firstname.lastname@example.org 202-509-0794
Alexander Young, MD MSHS UCLA Center for Health Services and Society 10920 Wilshire Blvd., Suite 300 Los Angeles, CA 90024 310-794-7219
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ameritoxs-ingenuity-health-announces-research-study-from-ucla-center-for-health-services-and-society-300362920.html
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All